Traumatic brain injury (TBI) is one of the biggest challenges in the world of healthcare at this point, and there are some companies that are working on solutions for it. One of the companies to have been working on it is Halberd Corporation (OTC: HALB), and on September 20, the company made a major new announcement with regards to that project.

It announced at the time that it had joined hands with Athena GTX for the purpose of developing solutions directed at TBI and the eventual submission of those solutions for government contracts. The project would be underpinned by the path-breaking proprietary nasal spray for the mitigation of the effects of TBI from Halberd.

TBI is a life-changing and serious condition that affects many people, in addition to athletes, first responders, and military personnel, among others. The company is currently involved in the development of its unique nasal spray, and in fact, the testing of the product is being conducted by Mississippi State University. The crux of the treatment lies in the suppression of the inflammatory neurotransmitters and cytokines that originate as a consequence of TBI.

Research has revealed that if those elements stay at elevated levels, then there is a danger of permanent alterations to the brain. For instance, it can lead to a wide range of serious health issues like early-stage Alzheimer’s disease, post-traumatic stress disorder (PTSD), suicide ideation, and other neurodegenerative conditions.

In the news release, the company noted that through its collaboration with Athena, it would advance solutions related to the treatment of TBI. The goal of both Halberd and Athena is to provide a solution to TBI at the point of injury, which could bring about a path-breaking change in how such injuries are treated.